Literature DB >> 34740385

Serum Buprenorphine Concentrations and Behavioral Activity in Mice After a Single Subcutaneous Injection of Simbadol, Buprenorphine SR-LAB, or Standard Buprenorphine.

Page H Myers1, David R Goulding1, Rebecca A Wiltshire1, Christopher A McGee1, Angela B Dickerson1, Molly M Comins1, Min Shi2, Grace E Kissling2, Fred B Lih3, Leesa J Deterding3, Kathy E Laber-Laird1, Terry L Blankenship-Paris1.   

Abstract

Buprenorphine, an analgesic commonly used in rodent surgery, requires repeated dosing every 4 to 6 h in order to provide adequate analgesia. However, redosing requires repeated handling, which may itself cause stress. Buprenorphine SR-LAB, which reportedly maintains serum levels of buprenorphine greater than 1 ng/mL for 48 to 72 h, is commercially available. However, the viscosity of the product and small dosing volumes make accurate dosing a challenge. Simbadol is a concentrated formulation of buprenorphine hydrochloride labeled for use in cats with recommended dosing frequency of every 24 h. We measured serum concentrations over time after a single injection of this product in C57BL/6NCrl mice and compared it to standard buprenorphine (Buprenex) and Buprenorphine SR-LAB. Male and female mice were injected subcutaneously with one of the 3 buprenorphine formulations at a dose of 1 mg/kg at time 0. Groups of mice (n = 8) were euthanized at 1, 4, 8, 12, 16 h for all groups and 24 h for the Simbadol and the Buprenorphine SR-LAB. Liquid chromatography-mass spectrometry (LC-MS/MS) was used to determine concentrations of buprenorphine in each serum sample. High concentrations were observed in both Simbadol and standard buprenorphine groups one hour after injection (>50 ng/mL). These groups had similar buprenorphine concentration curves, including rates of decline. The standard buprenorphine group had mean concentrations less than 1 ng/mL by 12 h and the Simbadol group by 16 h. In contrast, the Buprenorphine SR-LAB group remained above the 1 ng/mL therapeutic threshold throughout the 24 h. In addition, clinical signs, including increased activity, that lasted for up to an hour after the injection in the Simbadol and standard buprenorphine groups. We conclude that Simbadol does not offer dosing advantages over the standard buprenorphine formulation when given at 1 mg/kg. Buprenorphine SR-LAB maintained a steady concentration of buprenorphine above 1 ng/mL for at least 24 h, and as such is a superior choice for providing long-term analgesia.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34740385      PMCID: PMC8628526          DOI: 10.30802/AALAS-JAALAS-21-000028

Source DB:  PubMed          Journal:  J Am Assoc Lab Anim Sci        ISSN: 1559-6109            Impact factor:   1.232


  29 in total

1.  Evaluation of an improved sustained-release buprenorphine formulation for use in mice.

Authors:  Jason R Healy; Jennifer L Tonkin; Stacey R Kamarec; Mitchell A Saludes; Sherif Y Ibrahim; Rae R Matsumoto; Jeffrey H Wimsatt
Journal:  Am J Vet Res       Date:  2014-07       Impact factor: 1.156

2.  Evaluation of self-injurious behavior, thermal sensitivity, food intake, fecal output, and pica after injection of three buprenorphine formulations in rats (Rattus norvegicus).

Authors:  Molly Allen; Rebecca A Johnson
Journal:  Am J Vet Res       Date:  2018-07       Impact factor: 1.156

3.  Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain.

Authors:  Thomas Christoph; Babette Kögel; Klaus Schiene; Murielle Méen; Jean De Vry; Elmar Friderichs
Journal:  Eur J Pharmacol       Date:  2004-12-30       Impact factor: 4.432

4.  The magnitude and duration of the analgesic effect of morphine, butorphanol, and buprenorphine in rats and mice.

Authors:  N M Gades; P J Danneman; S K Wixson; E A Tolley
Journal:  Contemp Top Lab Anim Sci       Date:  2000-03

Review 5.  Buprenorphine: new pharmacological aspects.

Authors:  Alan Cowan
Journal:  Int J Clin Pract Suppl       Date:  2003-02

6.  Pharmacokinetics and Paw Withdrawal Pressure in Female Guinea Pigs (Cavia porcellus) Treated with Sustained-Release Buprenorphine and Buprenorphine Hydrochloride.

Authors:  Brian J Smith; Daniel J Wegenast; Ryan J Hansen; Ann M Hess; Lon V Kendall
Journal:  J Am Assoc Lab Anim Sci       Date:  2016-11       Impact factor: 1.232

7.  Evaluation of a sustained-release formulation of buprenorphine for analgesia in rats.

Authors:  Patricia L Foley; Haixiang Liang; Andrew R Crichlow
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-03       Impact factor: 1.232

8.  The animal pharmacology of buprenorphine, an oripavine analgesic agent.

Authors:  A Cowan; J C Doxey; E J Harry
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

9.  Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats.

Authors:  Graeme M Doodnaught; Beatriz P Monteiro; Javier Benito; Daniel Edge; Francis Beaudry; Ludovic Pelligand; Paulo Steagall
Journal:  PLoS One       Date:  2017-04-26       Impact factor: 3.240

10.  Effects of repetitive gentle handling of male C57BL/6NCrl mice on comparative behavioural test results.

Authors:  Hiroshi Ueno; Yu Takahashi; Shunsuke Suemitsu; Shinji Murakami; Naoya Kitamura; Kenta Wani; Yosuke Matsumoto; Motoi Okamoto; Takeshi Ishihara
Journal:  Sci Rep       Date:  2020-02-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.